Skip to main content
. 2023 Dec 1;133(23):e167728. doi: 10.1172/JCI167728

Figure 5. ATXN3 inhibition improves the preclinical efficacy of anti–PD-1 therapy.

Figure 5

(A and B) Scheme representing the experimental procedure (A) and tumor growth curves (B) of C57BL/6 mice injected subcutaneously with WT or ATXN3-KO LLC1 cells and treated with PD-1 antibody (25 μg per mouse, once every 2 days, n = 5). (C–E) Tumor photograph (C), tumor growth curves (D), and tumor burdens (E) for C57BL/6 mice bearing LLC1 tumors treated with PD-1 antibody (50 μg per mouse, once every 2 days, n = 10). (F) Representative flow staining of CD4+ T cells, CD8+ T cells, and IFN-γ+CD8+ T cells in CD45+ T cell populations from LLC1 tumors (n = 10) as described in C and D. (G–I) Quantification of CD4+ T cell (F), CD8+ T cell (G), and IFN-γ+CD8+ T cell (H) percentage in CD45+ populations from LLC1 tumors (n = 10) as described in C and D. (J and K) C57BL/6 mice (6–8 weeks) were injected subcutaneously with WT or ATXN3-KO LLC1 cells and treated with PD-1 antibody (100 μg per mouse, once every 2 days, n = 5). Tumor growth curve was measured every 2 days (J), and mouse tumors were weighed at the end of the experiment (K). B, D, E, and G–K: Ordinary 1-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.